CLE-400 Drug Asset Due Diligence Report 2026

This CLE-400 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 11 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether CLE-400 can convert its Small molecule drug profile and H4 receptor x SSTR4 x α2A-AR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	CLE-400 (query alias: CLE-400)
Modality / target	Small molecule drug; H4 receptor x SSTR4 x α2A-AR; H4 receptor agonists, SSTR4 agonists, α2A-AR agonists
Highest global status	Phase 2
Originator	Clexio Biosciences Ltd.
Active developers	Clexio Biosciences Ltd.

The MCP disease footprint includes Pruritus, Diabetic Neuropathies. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06262607	Phase 2	Completed	59	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-Design, Phase 2 Study to Assess the Efficacy and Safety of CLE-400 Topical Gel for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica

Phase 2; n=59; evaluation: Not stated in English source. Reported fields: Percent Change From Baseline in Weekly Mean of the Daily 24-hour Worst Itch-Numeric Rating Scale (WI-NRS) Score at Week 4.(LS Mean) = -44.37 percentage of change from baseline ; Percent Change From Baseline in Weekly Mean of the Daily 24-hour Worst Itch-Numeric Rating Scale (WI-NRS) Score at Week 4.(LS Mean) = -50.37 percentage of change from baseline

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

CLE-400 addresses Pruritus, Diabetic Neuropathies. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 3 matched transaction record(s) under the scope “target-level comparable: H4 receptor x SSTR4 x α2A-AR.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: H4 receptor x SSTR4 x α2A-AR records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2022-03-09	Durham University collaborates with Akari Therapeutics to pursue the development of votucalis for the treatment of pain and itch.	Preclinical	Financial terms not disclosed
2018-08-24	JW Pharmaceutical signs global out-licensing agreement for their novel atopic dermatitis drug candidate, JW1601, with LEO Pharma, a global leader in medical dermatology	Preclinical	US$17.0M upfront; US$385.0M milestones; US$402.0M stated total
2012-07-30	Palau Pharma signs an exclusive option agreement with Sensorion Pharmaceuticals for the development of Palau´s histamine-4 receptor antagonist, UR-63325	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO